Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States
In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations a...
Gespeichert in:
| Veröffentlicht in: | Infectious diseases and therapy 2024-12 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Infectious diseases and therapy |
| container_volume | |
| creator | Wilson, Amanda Rahai, Neloufar Beck, Ekkehard Beebe, Elisha Conroy, Brian Esposito, Daina Govil, Priya Kopel, Hagit Lu, Tianyi Mansi, James Marks, Morgan A Mues, Katherine E Shah, Rohan Skornicki, Michelle Sun, Tianyu Toyip, Astra Yousefi, Mitra Martin, David Araujo, Andre B |
| description | In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years.
This observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023-2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE).
The study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48-54%). Subgroup analyses showed a VE of 56% (95% CI 51-61%) among adults ≥ 65 years and 46% (95% CI 39-52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24-27%). Time-varying analyses showed that while VE declined over time, VE remained significant.
During the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety. |
| doi_str_mv | 10.1007/s40121-024-01091-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3147975461</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3147975461</sourcerecordid><originalsourceid>FETCH-LOGICAL-p569-a6c4e2a1fb85c0299b23d792084860e62fdc797491d0f288c6c8d61e230be2963</originalsourceid><addsrcrecordid>eNo1kDtOAzEURV2ASBSyAQrkksbg5_nZ5SgEEikiEgQkqsgz8yYYzY_YEwkqOpRd0LARlpKVMILQvNuce670CDkBfg6cRxfW5yCAceEzDlwBgwPSF6A8JoVQPTK09pnzjpE-qOiI9DwVcckD1Scf440uWu1MtaLuCek4zzF1ZoMVWkvrnJa3NzEDEXnnEgIar7SprKOj-cP0koGik9o2xunCvHWOuqJxWXemOGsLZzsas937drf96i7I789H1GtLTfU7dV8Zhxm9c9qhPSaHuS4sDvc5IIur8WI0YbP59XQUz1gThIrpMPVRaMgTGaRcKJUIL4uU4NKXIcdQ5FkaqchXkPFcSJmGqcxCQOHxBIUKvQE5-9M26_qlReuWpbEpFoWusG7t0gO_6wd-CB16ukfbpMRs2axNqdevy__feT8TN3Eg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3147975461</pqid></control><display><type>article</type><title>Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>Springer Nature OA Free Journals</source><creator>Wilson, Amanda ; Rahai, Neloufar ; Beck, Ekkehard ; Beebe, Elisha ; Conroy, Brian ; Esposito, Daina ; Govil, Priya ; Kopel, Hagit ; Lu, Tianyi ; Mansi, James ; Marks, Morgan A ; Mues, Katherine E ; Shah, Rohan ; Skornicki, Michelle ; Sun, Tianyu ; Toyip, Astra ; Yousefi, Mitra ; Martin, David ; Araujo, Andre B</creator><creatorcontrib>Wilson, Amanda ; Rahai, Neloufar ; Beck, Ekkehard ; Beebe, Elisha ; Conroy, Brian ; Esposito, Daina ; Govil, Priya ; Kopel, Hagit ; Lu, Tianyi ; Mansi, James ; Marks, Morgan A ; Mues, Katherine E ; Shah, Rohan ; Skornicki, Michelle ; Sun, Tianyu ; Toyip, Astra ; Yousefi, Mitra ; Martin, David ; Araujo, Andre B</creatorcontrib><description>In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years.
This observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023-2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE).
The study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48-54%). Subgroup analyses showed a VE of 56% (95% CI 51-61%) among adults ≥ 65 years and 46% (95% CI 39-52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24-27%). Time-varying analyses showed that while VE declined over time, VE remained significant.
During the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.</description><identifier>ISSN: 2193-8229</identifier><identifier>DOI: 10.1007/s40121-024-01091-1</identifier><identifier>PMID: 39708059</identifier><language>eng</language><publisher>New Zealand</publisher><ispartof>Infectious diseases and therapy, 2024-12</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-4430-560X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39708059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilson, Amanda</creatorcontrib><creatorcontrib>Rahai, Neloufar</creatorcontrib><creatorcontrib>Beck, Ekkehard</creatorcontrib><creatorcontrib>Beebe, Elisha</creatorcontrib><creatorcontrib>Conroy, Brian</creatorcontrib><creatorcontrib>Esposito, Daina</creatorcontrib><creatorcontrib>Govil, Priya</creatorcontrib><creatorcontrib>Kopel, Hagit</creatorcontrib><creatorcontrib>Lu, Tianyi</creatorcontrib><creatorcontrib>Mansi, James</creatorcontrib><creatorcontrib>Marks, Morgan A</creatorcontrib><creatorcontrib>Mues, Katherine E</creatorcontrib><creatorcontrib>Shah, Rohan</creatorcontrib><creatorcontrib>Skornicki, Michelle</creatorcontrib><creatorcontrib>Sun, Tianyu</creatorcontrib><creatorcontrib>Toyip, Astra</creatorcontrib><creatorcontrib>Yousefi, Mitra</creatorcontrib><creatorcontrib>Martin, David</creatorcontrib><creatorcontrib>Araujo, Andre B</creatorcontrib><title>Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States</title><title>Infectious diseases and therapy</title><addtitle>Infect Dis Ther</addtitle><description>In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years.
This observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023-2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE).
The study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48-54%). Subgroup analyses showed a VE of 56% (95% CI 51-61%) among adults ≥ 65 years and 46% (95% CI 39-52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24-27%). Time-varying analyses showed that while VE declined over time, VE remained significant.
During the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.</description><issn>2193-8229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo1kDtOAzEURV2ASBSyAQrkksbg5_nZ5SgEEikiEgQkqsgz8yYYzY_YEwkqOpRd0LARlpKVMILQvNuce670CDkBfg6cRxfW5yCAceEzDlwBgwPSF6A8JoVQPTK09pnzjpE-qOiI9DwVcckD1Scf440uWu1MtaLuCek4zzF1ZoMVWkvrnJa3NzEDEXnnEgIar7SprKOj-cP0koGik9o2xunCvHWOuqJxWXemOGsLZzsas937drf96i7I789H1GtLTfU7dV8Zhxm9c9qhPSaHuS4sDvc5IIur8WI0YbP59XQUz1gThIrpMPVRaMgTGaRcKJUIL4uU4NKXIcdQ5FkaqchXkPFcSJmGqcxCQOHxBIUKvQE5-9M26_qlReuWpbEpFoWusG7t0gO_6wd-CB16ukfbpMRs2axNqdevy__feT8TN3Eg</recordid><startdate>20241221</startdate><enddate>20241221</enddate><creator>Wilson, Amanda</creator><creator>Rahai, Neloufar</creator><creator>Beck, Ekkehard</creator><creator>Beebe, Elisha</creator><creator>Conroy, Brian</creator><creator>Esposito, Daina</creator><creator>Govil, Priya</creator><creator>Kopel, Hagit</creator><creator>Lu, Tianyi</creator><creator>Mansi, James</creator><creator>Marks, Morgan A</creator><creator>Mues, Katherine E</creator><creator>Shah, Rohan</creator><creator>Skornicki, Michelle</creator><creator>Sun, Tianyu</creator><creator>Toyip, Astra</creator><creator>Yousefi, Mitra</creator><creator>Martin, David</creator><creator>Araujo, Andre B</creator><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4430-560X</orcidid></search><sort><creationdate>20241221</creationdate><title>Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States</title><author>Wilson, Amanda ; Rahai, Neloufar ; Beck, Ekkehard ; Beebe, Elisha ; Conroy, Brian ; Esposito, Daina ; Govil, Priya ; Kopel, Hagit ; Lu, Tianyi ; Mansi, James ; Marks, Morgan A ; Mues, Katherine E ; Shah, Rohan ; Skornicki, Michelle ; Sun, Tianyu ; Toyip, Astra ; Yousefi, Mitra ; Martin, David ; Araujo, Andre B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p569-a6c4e2a1fb85c0299b23d792084860e62fdc797491d0f288c6c8d61e230be2963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilson, Amanda</creatorcontrib><creatorcontrib>Rahai, Neloufar</creatorcontrib><creatorcontrib>Beck, Ekkehard</creatorcontrib><creatorcontrib>Beebe, Elisha</creatorcontrib><creatorcontrib>Conroy, Brian</creatorcontrib><creatorcontrib>Esposito, Daina</creatorcontrib><creatorcontrib>Govil, Priya</creatorcontrib><creatorcontrib>Kopel, Hagit</creatorcontrib><creatorcontrib>Lu, Tianyi</creatorcontrib><creatorcontrib>Mansi, James</creatorcontrib><creatorcontrib>Marks, Morgan A</creatorcontrib><creatorcontrib>Mues, Katherine E</creatorcontrib><creatorcontrib>Shah, Rohan</creatorcontrib><creatorcontrib>Skornicki, Michelle</creatorcontrib><creatorcontrib>Sun, Tianyu</creatorcontrib><creatorcontrib>Toyip, Astra</creatorcontrib><creatorcontrib>Yousefi, Mitra</creatorcontrib><creatorcontrib>Martin, David</creatorcontrib><creatorcontrib>Araujo, Andre B</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Infectious diseases and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilson, Amanda</au><au>Rahai, Neloufar</au><au>Beck, Ekkehard</au><au>Beebe, Elisha</au><au>Conroy, Brian</au><au>Esposito, Daina</au><au>Govil, Priya</au><au>Kopel, Hagit</au><au>Lu, Tianyi</au><au>Mansi, James</au><au>Marks, Morgan A</au><au>Mues, Katherine E</au><au>Shah, Rohan</au><au>Skornicki, Michelle</au><au>Sun, Tianyu</au><au>Toyip, Astra</au><au>Yousefi, Mitra</au><au>Martin, David</au><au>Araujo, Andre B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States</atitle><jtitle>Infectious diseases and therapy</jtitle><addtitle>Infect Dis Ther</addtitle><date>2024-12-21</date><risdate>2024</risdate><issn>2193-8229</issn><abstract>In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years.
This observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023-2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE).
The study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48-54%). Subgroup analyses showed a VE of 56% (95% CI 51-61%) among adults ≥ 65 years and 46% (95% CI 39-52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24-27%). Time-varying analyses showed that while VE declined over time, VE remained significant.
During the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.</abstract><cop>New Zealand</cop><pmid>39708059</pmid><doi>10.1007/s40121-024-01091-1</doi><orcidid>https://orcid.org/0000-0003-4430-560X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2193-8229 |
| ispartof | Infectious diseases and therapy, 2024-12 |
| issn | 2193-8229 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3147975461 |
| source | DOAJ Directory of Open Access Journals; PubMed Central; EZB Electronic Journals Library; Springer Nature OA Free Journals |
| title | Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A36%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20the%20Effectiveness%20of%20mRNA-1273.815%20Against%20COVID-19%20Hospitalization%20Among%20Adults%20Aged%E2%80%89%E2%89%A5%E2%80%8918%C2%A0Years%20in%20the%20United%20States&rft.jtitle=Infectious%20diseases%20and%20therapy&rft.au=Wilson,%20Amanda&rft.date=2024-12-21&rft.issn=2193-8229&rft_id=info:doi/10.1007/s40121-024-01091-1&rft_dat=%3Cproquest_pubme%3E3147975461%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3147975461&rft_id=info:pmid/39708059&rfr_iscdi=true |